NorthWest Biotherapeutics Inc (NWBO)

[longfellow95]

Merck really has no idea how to increase response rates to Keytruda, without introducing further toxicity.

Do you know how many Keytruda combo trials are planned or ongoing?
Hundreds..

So they are just employing a scattergun approach, in the hopes that something works.
PDL-1 is a very inaccurate biomarker.

The Moderna link-up may well come to nothing.

And it is not even the only neo-antigen based vaccine, they are partnering with. (Neon Neo-PV-01 being the other.)

Over the full range of histologies, the ICI's have average response rates of about 20%. And that could mean just a couple of months without tumor growth, before treatment effect peters out.
And disease progression resumes..

And ICI's accelerate disease progression (and death), in perhaps 10% of all patients.